Key result
Statin therapy stabilized lipid-rich plaques irrespective of age, but older patients (≥57 years) showed a delayed reduction in lipid content and no significant decrease in total atheroma volume.
Why the study?
Does age affect the vascular response of lipid-rich plaques to intensive versus moderate statin therapy?
Observational (n=69)
Does age affect the vascular response of lipid-rich plaques to intensive versus moderate statin therapy?
Intensive statin therapy is more effective than moderate therapy at increasing fibrous-cap thickness in older patients, although older patients exhibit a delayed reduction in lipid content compared to younger patients.
Answers are grounded in this paper and cite their sources.
Age may delay plaque lipid reduction; leaves open whether intensive statins benefit older patients differently.
OBJECTIVE: Age-related structural and functional changes in vessel wall may affect the time course of vascular response to statin therapy. In this study, we sought to compare the response of lipid-rich plaque to statin therapy in elderly versus younger patients using optical coherence tomography and intravascular ultrasound. PATIENTS AND METHODS: Sixty-nine patients who underwent serial optical coherence tomography and intravascular ultrasound at the time point of baseline, 6, and 12 months were divided into two groups according to median age: group A (age<57 years, n=35) and group B (age≥57 years, n=34). Patients were treated with intensive (atorvastatin 60 mg/day) or moderate (atorvastatin 20 mg/day or rosuvastatin 10 mg/day) statin therapy. RESULTS: A continuous increase in fibrous-cap thickness (FCT) from baseline to 12 months was observed in both groups (P<0.001, <0.001, respectively). Intensive statin induced greater percent change in FCT at 12 months than moderate statin in group B (P=0.020), but not in group A (P=0.251). Mean lipid arc decreased significantly at 12 months in two groups (P<0.001, <0.001, respectively), and this response was delayed for 6 months (P=0.403) and began to decrease during the second 6 months (P<0.001) in group B. Normalized total atheroma volume decreased significantly in group A (P<0.001), but not in group B (P=0.349). CONCLUSION: Statin therapy could stabilize lipid-rich plaque irrespective of age, and intensive statin therapy was more effective than a moderate dose of statin in increasing FCT, particularly in older patients. A delayed response of lipid content and unfavorable change in normalized total atheroma volume to statin were observed in elderly patients.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2017) conducted an observational in Lipid-rich plaque (n=69). Age ≥57 years vs. Age <57 years was evaluated on Change in fibrous-cap thickness (FCT), mean lipid arc, and normalized total atheroma volume. Statin therapy stabilized lipid-rich plaques irrespective of age, but older patients (≥57 years) showed a delayed reduction in lipid content and no significant decrease in total atheroma volume.
Synapse has enriched 10 related papers. Consider them for comparative context: